Literature DB >> 29982771

Opening an onconephrology clinic: recommendations and basic requirements.

Laura Cosmai1, Camillo Porta2, Mark A Perazella3, Vincent Launay-Vacher4, Mitchell H Rosner5, Kenar D Jhaveri6, Matteo Floris7, Antonello Pani7, Cécile Teuma8, Cèzary A Szczylik9, Maurizio Gallieni1,10.   

Abstract

Onconephrology is a rapidly evolving subspeciality that covers all areas of renal involvement in cancer patients. The complexity of the field may benefit from well-defined multidisciplinary management administered by a dedicated team. Since there is an increasing need to address the needs of this population in dedicated outpatient clinics, it is critical to highlight basic characteristics and to suggest areas of development. In this brief perspective article, we analyse the requirements of an onconephrology clinic in terms of logistics, critical mass of patients and building a multidisciplinary team. We will further discuss which patients to refer and which conditions to treat. The last part of the article is dedicated to education and performance indicators and to analysis of the potential advantages of applying the hub-and-spoke model to this field. The ultimate aim of this experience-based article is to initiate debate about what an onconephrology outpatient clinic might look like in order to ensure the highest quality of care for this growing population of patients.

Entities:  

Mesh:

Year:  2018        PMID: 29982771     DOI: 10.1093/ndt/gfy188

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

1.  Kidney Biopsy in Patients with Cancer along the Last Decade: A Multicenter Study.

Authors:  Mónica Bolufer; Clara García-Carro; Miquel Blasco; Luis F Quintana; Amir Shabaka; Cristina Rabasco; Juliana Draibe; Ana Merino; María Rosa Melero; Fabiola Alonso; Anna Buxeda; Paula Batalha; Maria Teresa Visús; Maria José Soler
Journal:  J Clin Med       Date:  2022-05-21       Impact factor: 4.964

Review 2.  Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function.

Authors:  Łukasz Mielczarek; Anna Brodziak; Paweł Sobczuk; Maciej Kawecki; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Cancer Chemother Pharmacol       Date:  2021-03-25       Impact factor: 3.333

3.  Cancer patterns and association with mortality and renal outcomes in non-dialysis dependent chronic kidney disease: a matched cohort study.

Authors:  Rajkumar Chinnadurai; Emma Flanagan; Gordon C Jayson; Philip A Kalra
Journal:  BMC Nephrol       Date:  2019-10-22       Impact factor: 2.388

Review 4.  Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations.

Authors:  Luca Piscitani; Vittorio Sirolli; Lorenzo Di Liberato; Manrico Morroni; Mario Bonomini
Journal:  Int J Mol Sci       Date:  2020-07-10       Impact factor: 5.923

5.  A Non-Infectious Uveitis Multidisciplinary Clinic in a Tertiary Referral Center: Clinical Impact and Added Value.

Authors:  Inês Leal; Vasco C Romão; Sofia Mano; Nikita Khmelinskii; Raquel Campanilho-Marques; Cristina Ponte; Carla Macieira; Filipa Oliveira-Ramos; Elsa Vieira-Sousa; Carlos Miranda Rosa; Walter Rodrigues; Luís Abegão Pinto; Carlos Marques-Neves; João Eurico Fonseca
Journal:  J Multidiscip Healthc       Date:  2021-03-22

6.  Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients.

Authors:  Chie Masaki; Kiminori Sugino; Sakiko Kobayashi; Yoshie Hosoi; Reiko Ono; Haruhiko Yamazaki; Junko Akaishi; Kiyomi Y Hames; Chisato Tomoda; Akifumi Suzuki; Kenichi Matsuzu; Keiko Ohkuwa; Wataru Kitagawa; Mitsuji Nagahama; Koichi Ito
Journal:  BMC Cancer       Date:  2021-08-05       Impact factor: 4.430

7.  Advancing Nephrology: Division Leaders Advise ASN.

Authors:  Gregory L Braden; Arlene Chapman; David H Ellison; Crystal A Gadegbeku; Susan B Gurley; Peter Igarashi; Ellie Kelepouris; Marva M Moxey-Mims; Mark D Okusa; Troy J Plumb; Susan E Quaggin; David J Salant; Mark S Segal; Stuart J Shankland; Stefan Somlo
Journal:  Clin J Am Soc Nephrol       Date:  2020-08-12       Impact factor: 8.237

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.